Dow Down0.56% Nasdaq Down0.79%

Alexion Pharmaceuticals, Inc. (ALXN)

141.41 Down 2.96(2.05%) May 4, 4:00PM EDT
|After Hours : 141.41 0.00 (0.00%) May 4, 5:09PM EDT
ProfileGet Profile for:
Alexion Pharmaceuticals, Inc.
100 College Street
New Haven, CT 06510
United States - Map
Phone: 203-272-2596
Fax: 203-271-8198

Index Membership:N/A
Full Time Employees:2,924

Business Summary 

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Alexion Pharmaceuticals, Inc.

Corporate Governance 
Alexion Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 2. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 1; Compensation: 3.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Leonard Bell M.D., 58
Co-Founder and Chairman
Mr. David L. Hallal , 50
Chief Exec. Officer and Director
Mr. Vikas Sinha M.B.A., C.A., CPA, 53
Chief Financial Officer and Exec. VP
Ms. Clare Carmichael , 56
Chief HR Officer and Exec. VP
Mr. John B. Moriarty Jr., J.D., 48
Exec. VP and Gen. Counsel
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders